Genmab
Aktiesnakken
TESLA
Genmab
NOVO
Forsvarsaktier
Bavarian Nordic
Biotek-snakken
Amerikanske aktier
Gubra
Medico
Shipping
Zealand Pharma
Vestas
Embla Medical
GN Store Nord
Grønne Aktier
Pharma
Politiksnakken
Banker og Finans
Ennogie
Laks
|
4/11 19:43 af E L |
epco abstract there now - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes (link)
|
|
|
4/11 19:41 af E L |
audio isn't great on this call, i hope you can hear it better than
me...
|
|
4/11 19:22 af Solsen |
Succes hele vejen rundt ;-)
|
|
|
4/11 18:54 af E L |
hmmm, the €20mn Curevac investment now worth dkk644mn...
|
|
|
4/11 18:41 af E L |
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease (PROACTIVE) (link)
|
|
|
4/11 18:39 af AaBforever |
Men spændende at se hvad der sker de næste timer/
dage i US.
|
|
4/11 18:38 af Helge Larsen/PI-redaktør |
|
|
|
4/11 18:36 af E L |
in august "Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease " (link)
|
|
|
4/11 18:36 af AaBforever |
Biotek...healthcare... ok i dag...tror også nohope er tilfreds..:-D
|
|
|
4/11 18:32 af E L |
and PRV-015 (AMG 714)
• Antibody targeting IL-15
• In clinical development for celiac disease
?
|
|
|
4/11 18:26 af GeorgeBest |
Sounds new E L
|
|
|
4/11 18:26 af E L |
it is in trial for Metastatic Castration-Resistant Prostate Cancer (link)
|
|
|
4/11 18:25 af E L |
Is this one new? JNJ-70218902
• Phase 1 study in advanced stage solid tumors ongoing
• Developed by Janssen under the DuoBody technology collaboration
/ JNJ-70218902 is a bispecific antibody created by Janssen using Genmab's DuoBody technology. It is
being investigated in a Phase 1 clinical study for the treatment of advanced stage solid tumors.
Third Quarter 2020 Update
• September: A Phase 1 study of JNJ-70218902 in patients with advanced solid tumors was
initiated.
|
|
|
4/11 18:21 af Helge Larsen/PI-redaktør |
Rapporten: (link)
|
|
|
4/11 18:19 af Helge Larsen/PI-redaktør |
|
|
|
4/11 18:16 af AaBforever |
Genmab overgår forventninger i tredje kvartal/Børsen
|
|
4/11 18:06 af nohope |
Spørger bare for at sige noget, skal ikke bruges til noget nyttigt.
|
|
|
4/11 18:05 af Helge Larsen/PI-redaktør |
Det tager kun få sekunder. :-)
|
|
|
4/11 18:05 af nohope |
Er det den største daglige stigning i kroner/point ?
|
|
|
4/11 18:04 af Helge Larsen/PI-redaktør |
Mens vi venter: Meld dig til Q&A med Genmab: (link)
|
|
|
4/11 18:03 af nohope |
Aha - Trump modellen - vi stopper med at tælle når jeg fører....
|
|
|
4/11 18:01 af nohope |
Nu er NBI jo ikke lukket endnu-
|
|
|
4/11 18:00 af AaBforever |
2347
|
|
|
4/11 18:00 af Stroka |
Det lugter af brændte shorts i dag. :-)
|
|
| ||
|
|
4/11 17:57 af Helge Larsen/PI-redaktør |
NBI: (link)
|
|
|
4/11 17:56 af Helge Larsen/PI-redaktør |
Slutauktionen er ikke forbi endnu. ;-)
|
|
|
4/11 17:53 af nohope |
Bortset fra det, så er en stigning på 7 % vel ikke imponerende - når NBI stiger 6 %
|
|
|
4/11 17:53 af nohope |
Trtump har sikkert for travlt til at kigge med i dag...
|
|
|
4/11 17:52 af Helge Larsen/PI-redaktør |
Nu er Italien også med. Vi mangler vores sædvanlige besøgende fra USA.
|
|
|
4/11 17:50 af Helge Larsen/PI-redaktør |
Godt vi fik installeret nye stærke servere i forsommeren. :-)
|
|
|
4/11 17:47 af Helge Larsen/PI-redaktør |
Besøgende i chatten lige nu:
1. Denmark 279
2. Luxembourg 2
3. Germany 1
4. Netherlands 11
5. Norway 1
6. Sweden 1
7. Turkey 1
8. United Arab Emirates
|
|
4/11 17:41 af StockBull |
AbbVie +9% - kanon dag
|
|
|
4/11 17:28 af E L |
i can't find that one online yet?
|
|
|
4/11 17:22 af E L |
Subcutaneous Epcoritamab Induces Complete Responses With an Encouraging Safety Profile Across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients With Prior CAR-T Therapy: Updated Dose-Escalation Data– Oral presentation,
|
|
|
4/11 17:21 af E L |
Genmab Announces Data to be Presented at 2020 ASH Annual Meeting (link)
|
|
|
4/11 17:18 af AaBforever |
Gen 6%...:-)
|
|
|
4/11 17:01 af Solsen |
Knock off your socks ;-)
|
|
4/11 15:54 af Bulder |
indeed, can't wait to see the outcome in combo with dara.
|
|
|
4/11 15:50 af E L |
looks good though, no?
|
|
|
4/11 15:50 af E L |
ORR was a bit higher at IV though, probably still have to jack up the SC dose a bit
|
|
|
4/11 15:49 af E L |
that is a good point. the PhII is also SC (link)
|
|
|
4/11 15:42 af Bulder |
|
|
|
4/11 15:41 af Bulder |
Yes, but only grade 1-2 with sc dosing. Amd it looks that they have decided for sc, as that is the chosen adm in the combination study.
|
|
|
4/11 15:33 af E L |
MTD has not been defined and dose escalation continues, with the study nearing a RP2D.
|
|
|
4/11 15:33 af E L |
very interesting. had Talquetamab as a lotery ticket, early data encouriging though, even though a few grade 3 crs
?
|
|
|
4/11 15:07 af E L |
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) (link)
|
|
|
4/11 14:55 af E L |
Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience
|
|
|
4/11 14:53 af E L |
i just picked 1 Dara abstract, too many to post all
|
|
|
4/11 14:27 af E L |
forget that last one, it is old offcourse
|
|
|
4/11 14:24 af E L |
Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment (link)
|